{"filing":{"accession_number":"0001104659-26-094896","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"armp-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812x8k.htm"},"events":[{"id":27231,"run_id":24806,"accession_number":"0001104659-26-094896","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Armata's financial results for Q2 2026 and six months ended June 30, 2026, furnished as Exhibit 99.1 under Item 2.02. The press release includes detailed financial statements (balance sheet, income statement), operational metrics, and clinical/regulatory milestones. The company reported Q2 net income of $74.1 million (driven by a $91.0 million non-cash gain on the Convertible Loan), increased cash position to $24.0 million, and significant progress on its AP-SA02 Phase 3 program including FDA Fast Track designation and pediatric study plan agreement.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28668,"accession_number":"0001104659-26-094896","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Armata's financial results for Q2 2026 and six months ended June 30, 2026, furnished as Exhibit 99.1 under Item 2.02. The press release includes detailed financial statements (balance sheet, income statement), operational metrics, and clinical/regulatory milestones. The company reported Q2 net income of $74.1 million (driven by a $91.0 million non-cash gain on the Convertible Loan), increased cash position to $24.0 million, and significant progress on its AP-SA02 Phase 3 program including FDA Fast Track designation and pediatric study plan agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:22:43.995193+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28668,"accession_number":"0001104659-26-094896","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Armata's financial results for Q2 2026 and six months ended June 30, 2026, furnished as Exhibit 99.1 under Item 2.02. The press release includes detailed financial statements (balance sheet, income statement), operational metrics, and clinical/regulatory milestones. The company reported Q2 net income of $74.1 million (driven by a $91.0 million non-cash gain on the Convertible Loan), increased cash position to $24.0 million, and significant progress on its AP-SA02 Phase 3 program including FDA Fast Track designation and pediatric study plan agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:22:43.995193+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-08-12"}]}